Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Myeloid 1

Conditions

Recurrence 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1

Interventions

Dexamethasone 266Lenalidomide 159daratumumab 137Bortezomib 114pomalidomide 91Calcium Dobesilate 86Cyclophosphamide 85carfilzomib 77Specimen Handling 46isatuximab 45fludarabine 43Biopsy 43belantamab mafodotin 42Magnetic Resonance Spectroscopy 38dexamethasone acetate 34dexamethasone 21-phosphate 34auricularum 33Melphalan 33talquetamab 29ixazomib 27iberdomide 27fludarabine phosphate 24selinexor 22elotuzumab 21Whole-Body Irradiation 17X-Rays 15venetoclax 14Mycophenolic Acid 13tocilizumab 12Stem Cell Transplantation 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
tapotoclax × Plasma cell × 1 year × Clear all
NCT02675452 2025-07-09

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

Amgen

Phase 1 Terminated
141 enrolled 46 charts
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡